Forest Ray

Ampel will use the signature to develop FibroGene, a fibromyalgia blood test that the company expects to launch next year.

The company is developing a nonsurgical approach to help increase testing rates and lower the time to diagnosis for endometriosis.

In the wake of last year's massive restructuring, Invitae is focused on developing its Personalized Cancer Monitoring product while integrating other oncology offerings.

The Hazel assay uses finger prick amounts of blood, from which it immediately separates plasma that can be shipped at room temperature for chromosomal analysis.

Results from the Global Alzheimer's Platform cross-sectional study are expected in July 2023 with a second longitudinal study to be finished by the end of 2024.

Strong Signatera volumes fueled revenue growth and helped lift the firm's financial guidance despite questions raised by California regulatory action.

Myriad expects new product launches, strategic mergers, positive reimbursement decisions, and rising test volumes to drive growth despite current sagging revenues.

UCLA researchers developed an extracellular vesicle-based surface protein assay for early-stage hepatocellular carcinoma.

Revenues rose 9 percent on test service growth, as the company’s net loss swelled to $21.7 million from $1.9 million in Q2 of last year. 

Strong growth in Signatera volumes drove higher revenues, and along with gains in market share, Natera increases its guidance.